Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Autologous CD34+-enriched HSPCs Transduced with VSV-G Encoding IFN-a2

Gene therapy · Gene replacement · developed by Genenta Science

Phase 1/2 Most advanced trial (none active)
GNTA Developer
1 Registered trials

What is Autologous CD34+-enriched HSPCs Transduced with VSV-G Encoding IFN-a2?

Temferon is autologous CD34+-enriched hematopoietic stem and progenitor cells transduced with a VSV-G pseudotyped vector encoding interferon-alpha-2. The engineered cells are designed to produce interferon-alpha-2 systemically. It is studied in glioblastoma multiforme.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Temferon
Drug type
Gene therapy
Mechanism
Gene replacement
Pathways
immune_activation
Therapy area
Oncology
Developer
Genenta Science (GNTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03866109 Phase 1/2 Glioblastoma Multiforme Terminated GNTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma Multiforme

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GNTA page.

Follow GNTA, the company behind Autologous CD34+-enriched HSPCs Transduced with VSV-G Encoding IFN-a2

See GNTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GNTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.